Lipid nanoemulsions

Our nanoparticle technology is the most versatile in the market

Reliable and efficient

Our nanoparticle emulsions are a patented product, with a stable and controlled production

We offer plenty of benefits to your molecule with the highest quality of emulsions. From hydrophobic to amphiphilic molecules, small or complex, we stabilise them and carry them to their target site.

Biocompatible

With different cell types and in vivo models like mice, rat and zebrafish

Stable

In different biological fluids, sera and cell culture media

High loading capacity

Ensuring the desired therapeutic effect

Efficient intracellular delivery

Overcoming biological barriers

Versatile

Able to carry a wide range of molecules

Technology

Applications

Nanoemulsion production

Assays

In vitro assays

  • Labeling of live cells
  • Tracking cell internalization
  • FRET studies
  • Intracellular delivery of therapeutic compounds
  • Therapeutic evaluation
  • Cytotoxicity studies

In vivo assays

  • Biodistribution evaluation
  • Therapeutic evaluation
  • Cell tracking

Drug delivery of

Small molecules
Proteins
Peptides
Nucleic acids

DIVERSA Technologies

Technical data

The facts and figures behind our nanoparticles

Our proprietary technology is based on lipidic emulsions with an easily controllable size and a narrow distribution. Our nanometric emulsions show great stability in different relevant biological fluids and biocompatibility with different cell types as well as in vivo models such as mouse, rat and zebrafish. They have high loading capacity and are versatile and capable of associating a wide variety of compounds as hydrophobic or amphiphilic small molecules, peptides, proteins, and oligonucleotides (such as DNA and RNA) showing great association efficacy and deliver them to their target site by overcoming biological barriers. DIVERSA’s technology can efficiently achieve the intracellular delivery of therapeutic molecules.

Characterization of size and surface charge expressed as zeta potential, measured by Dynamic Light Scattering (DLS) and ALD.

Morphology of DIVERSA’s technology observed by Scanning Transmission Electron Microscopy (STEM) and Cryogenic Transmission Electron Microscopy, Cryo-TEM.

Cell internalization in fibroblast of DIVTECH labeled with FluoGreen observed under confocal microscopy after 4 hour incubation. Cell internalization in H1650 spheroids of DIVTECH labeled in red observed under confocal microscopy after 6 hour incubation.

Blue: nuclei, red: fibronectin, green: DIVTECH.

Blue: nuclei, red: DIVTECH-Cy5, green: cell membranes.
Stability of DIVERSA’s technology in different biological relevant fluids.

Human plasma Simulated tear fluid Simulated synovial fluid Simulated gastric fluid Simulated intestinal fluid (SIF) Fed state SIF Fasted state SIF
DIVTECH
24 h*
24 h*
24 h*
6 h
4 h
4 h
24 h*
*End of the experiment, stable particles.

Long-term stability at room temperature (40 ºC, 75% RH) and under storage conditions (25 ºC, 60% RH) up to 6 months, and in different buffers and in culture media supplemented with FBS.

DIVERSA’s technology showed a great biocompatibility with different cell types and increasing concentrations of the nanosystems measured by Alamar assay. Evolution of body weight in mice injected with DIVTECH. Red arrow: one dose tail intravenous injection of 30 mg/kg (10 mg/mL DIVTECH concentration). Gray arrows: three consecutive dose tail intravenous injection of 60 mg/kg (20 mg/mL nanosystem concentration) at days 2, 4 and 6 (cumulative dose 180 mg/kg).
DIVERSA’s technology can associate a wide variety of compounds as hydrophobic or amphiphilic molecules, peptides, proteins, and oligonucleotides (such as DNA and RNA, among others) showing great association efficiencies.

Molecules Association efficiency
Small molecules
85-99 %
Peptides
70-99 %
Proteins
70-99 %
DNA/RNA
85-99 %

Publications

Latest work from our team

  • Masoumi F et al (2021). Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem. Pharmaceutics 13(9), 1507. 3390/pharmaceutics13091507
  • Díez-Villares et al. (2021). Biodistribution of 68/67Ga-Radiolabeled Sphingolipid Nanoemulsions by PET and SPECT Imaging. Int J Nanomedicine 16: 5923–5935. 10.2147/IJN.S316767
  • S. Díez-Villares et al. (2021). Manganese Ferrite Nanoparticles Encapsulated into Vitamin E/Sphingomyelin Nanoemulsions as Contrast Agents for High-Sensitive Magnetic Resonance Imaging. Adv Healthc Mater e2101019. 10.1002/adhm.202101019
  • L. Bouzo et al. (2021). Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer. Sci Rep 11: 17213. 10.1038/s41598-021-96578-z
  • L. Bouzo et al. (2020). In Vitro–In Silico Modeling Approach to Rationally Designed Simple and Versatile Drug Delivery Systems. J. Phys. Chem. B 124, 28, 5788–5800. 10.1021/acs.jpcb.0c02731
  • Nagachinta et al. (2020). Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics. Pharmaceutics 12(2), 189. 10.3390/pharmaceutics12020189